Active Ingredient History
Betahistine is an orally administered, centrally acting histamine H1 receptor agonist with partial H3 antagonistic activity. It is proposed that betahistine may reduce peripherally the asymmetric functioning of the sensory vestibular organs in addition to increasing vestibulocochlear blood flow by antagonising local H3 heteroreceptors. Betahistine acts centrally by enhancing histamine synthesis within tuberomammillary nuclei of the posterior hypothalamus and histamine release within vestibular nuclei through antagonism of H3 autoreceptors. This mechanism, together with less specific effects of betahistine on alertness regulation through cerebral H1 receptors, should promote and facilitate central vestibular compensation. Betahistine is used to treat the symptoms associated with Ménière's disease, a condition of the inner ear which causes, vertigo (dizziness), tinnitus (ringing in the ears), hearing loss. NCATS
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Meniere Disease (approved 1968)
Affective Disorders, Psychotic (Phase 2)
Anemia (Phase 4)
Autism Spectrum Disorder (Phase 2)
Bipolar Disorder (Phase 2)
Depression (Phase 2)
Dyslipidemias (Phase 3)
Healthy Volunteers (Phase 1)
Hypercholesterolemia (Phase 2)
Hypophosphatemia (Phase 4)
Iron Deficiencies (Phase 4)
Meniere Disease (Phase 4)
Obesity (Phase 3)
Overnutrition (Phase 1)
Overweight (Phase 1)
Postural Balance (Phase 4)
Psychotic Disorders (Phase 2)
Schizophrenia (Phase 2)
Vertigo (Phase 4)
Weight Gain (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue